No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis

Cheema, Huzaifa Ahmad; Shafiee, Arman; Athar, Mohammad Mobin Teymouri; Shahid, Abia; Awan, Rehmat Ullah; Afifi, Ahmed M.; Shah, Jaffer; Jalal, Prasun K.

doi:10.1016/j.jinf.2022.11.022

Cited by 20 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…alternative therapeutic strategies to treat COVID-19 in diverse clinical settings; however, attempts to repurpose medications for COVID-19 have largely been met with failure. 11,12 Globally, as of 6 December 2022, there have been 642 million confirmed cases of COVID-19, including 6.6 million deaths, reported to WHO. 13 Clinical manifestations include fever, cough, dyspnoea, and neurological and dermatological symptoms; while anxiety, depression, hair loss, palpitations and chest pain have been reported to persist as long COVID symptoms in COVID-19 survivors.…”

mentioning

confidence: 99%

Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Cheema

Sohail

Fatima

et al. 2023

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Currently approved therapies for COVID‐19 are mostly limited by their low availability, high costs or the requirement of parenteral administration by trained medical personnel in an in‐hospital setting. Quercetin is a cheap and easily accessible therapeutic option for COVID‐19 patients. However, it has not been evaluated in a systematic review until now. We aimed to conduct a meta‐analysis to assess the effect of quercetin on clinical outcomes in COVID‐19 patients. Various databases including PubMed, the Cochrane Library and Embase were searched from inception until 5 October 2022 and results from six randomized controlled trials (RCTs) were pooled using a random‐effects model. All analyses were conducted using RevMan 5.4 with odds ratio (OR) as the effect measure. Quercetin decreased the risk of intensive care unit admission (OR = 0.31; 95% confidence interval (CI) 0.10–0.99) and the incidence of hospitalisation (OR = 0.25; 95% CI 0.10–0.62) but did not decrease the risk of all‐cause mortality and the rate of no recovery. Quercetin may be of benefit in COVID‐19 patients, especially if administered in its phytosome formulation which greatly enhances its bioavailability but large‐scale RCTs are needed to confirm these findings.

show abstract

mentioning

confidence: 99%

Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Cheema

Sohail

Fatima

et al. 2023

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The potential benefit of the H1 histamine receptor blocker Desloratadine is suggested by the measured decline in phospho-p38 and by inhibition of the SPRBD effects on expression of CHST15, CHST11 and ARSB, as well as by pharmacological studies that identified desloratadine/loratadine as a mechanism-based target [36][37][38]. Several clinical studies of H2 blockers on the response in Covid-19 have been reported and additional studies of antihistamines are ongoing [57][58][59].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Spike Protein Receptor Binding-ACE2 Interaction Increases Carbohydrate Sulfotransferases and Reduces N-Acetylgalactosamine-4-Sulfatase through Phospho-p38-MAPK and RB-E2F1

Tobacman

Bhattacharyya

2023

Preprint

View full text Add to dashboard Cite

Immunostaining in lungs of patients who died with Covid-19 infection showed increased intensity and distribution of chondroitin sulfate and carbohydrate sulfotransferase (CHST)15 and decline in N-acetylgalactostamine-4-sulfatase (Arylsulfatase B; ARSB). To explain these findings, human small airway epithelial cells were exposed to the SARS-CoV-2 spike protein receptor binding domain (SPRBD) and transcriptional mechanisms investigated. Phospho-p38 MAPK and phospho-Smad3 increased following exposure to the SPRBD, and their inhibition suppressed CHST15 and CHST11 promoter activation. Decline in ARSB was mediated by phospho-38 MAPK-induced N-terminal Rb phosphorylation and the associated decline in E2F1 binding to the ARSB promoter. The increases in chondroitin sulfotransferases were inhibited by the p38-MAPK inhibitor SB203580 and by the Smad3 inhibitor SIS3 and by treatment with the antihistamine desloratadine and the antibiotic monensin. Since accumulation of chondroitin sulfates is associated with fibrotic lung conditions and diffuse alveolar damage, increased attention to p38-MAPK inhibitors may be beneficial in Covid-19 infection.

show abstract

“…COVID‐19 has been found to affect not only the respiratory system, but also a range of other organs, including the cardiovascular, immune, and urinary systems, leading to a variety of disorders such as coagulopathy, disseminated intravascular coagulation, sepsis, and acute kidney injury 3,4 . Initially, the primary measures to combat COVID‐19 were self‐distancing, mask‐wearing, and isolating infected patients, however, the advent of the first vaccines in December 2020 marked a significant turning point in the fight against the pandemic, as they have been shown to reduce the escalation of both the number of deaths and the severity of the disease 5–8 . Since then, over 11 billion vaccine doses have been administered worldwide 9,10 .…”

Section: Introductionmentioning

confidence: 99%

The effect of COVID‐19 and COVID‐19 vaccination on serum anti‐Mullerian hormone: A systematic review and meta‐analysis

Ghaemi,

Hantoushzadeh,

Shafiee

et al. 2024

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

ObjectiveThe current study aims to evaluate the impact of COVID‐19 infection and vaccination on ovarian reserve by detecting the anti‐Mullerian hormone (AMH) level.MethodPubMed, Embase, Web of Science, and Scopus has been searched for studies assessing the effect of COVID‐19 infection and/or vaccination on AMH levels up to February 27, 2023. Based on PRISMA 2020 statement criteria, a systematic review and meta‐analysis of included studies were performed. The studies' quality was assessed by the National Institute of Health (NIH) quality assessment tool. The standardized mean difference (MD) of the AMH level was used and the quantitative values of each study were pooled separately by using a random effect model.ResultsOut of 246 studies screened, 18 were included in the systematic review and 14 in the meta‐analysis. Included studies were published between 2021 and 2022 and were conducted in different countries, including the USA (n = 3), China (n = 2), Russia (n = 2), Turkey (n = 5), Israel (n = 3), Czech (n = 2), and Spain (n = 1). Eight studies investigated the effect of SARS‐CoV‐2 infection on AMH levels, and ten studies investigated the possible effect of COVID‐19 vaccination on AMH levels. The pooled analysis showed a statistically significant decrease in AMH levels after COVID‐19 infection (SMD: −0.24; 95% CI: −0.36 to −0.11; I2 = 0%; p = .0003). Vaccination analysis showed a nonstatistically significant change in AMH levels after COVID‐19 vaccination (SMD: −0.11; 95% CI: −0.25 to 0.04; I2 = 35%; p = .14).ConclusionCOVID‐19 infection can result in ovarian reserve injury by reducing the AMH level but getting vaccinated against COVID‐19 has no impact on the AMH level.

show abstract

No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis

Cited by 20 publications

References 12 publications

Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

SARS-CoV-2 Spike Protein Receptor Binding-ACE2 Interaction Increases Carbohydrate Sulfotransferases and Reduces N-Acetylgalactosamine-4-Sulfatase through Phospho-p38-MAPK and RB-E2F1

The effect of COVID‐19 and COVID‐19 vaccination on serum anti‐Mullerian hormone: A systematic review and meta‐analysis

Contact Info

Product

Resources

About